PL3515924T3 - Krystaliczne postacie - Google Patents

Krystaliczne postacie

Info

Publication number
PL3515924T3
PL3515924T3 PL17771436T PL17771436T PL3515924T3 PL 3515924 T3 PL3515924 T3 PL 3515924T3 PL 17771436 T PL17771436 T PL 17771436T PL 17771436 T PL17771436 T PL 17771436T PL 3515924 T3 PL3515924 T3 PL 3515924T3
Authority
PL
Poland
Prior art keywords
crystalline forms
crystalline
forms
Prior art date
Application number
PL17771436T
Other languages
English (en)
Inventor
Daniel Leuenberger
Stefan Reber
Markus Von Raumer
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of PL3515924T3 publication Critical patent/PL3515924T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL17771436T 2016-09-22 2017-09-21 Krystaliczne postacie PL3515924T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
EP17771436.7A EP3515924B1 (en) 2016-09-22 2017-09-21 Crystalline forms
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (1)

Publication Number Publication Date
PL3515924T3 true PL3515924T3 (pl) 2022-04-11

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17771436T PL3515924T3 (pl) 2016-09-22 2017-09-21 Krystaliczne postacie

Country Status (27)

Country Link
US (4) US10730896B2 (pl)
EP (2) EP3515924B1 (pl)
JP (1) JP7097369B2 (pl)
KR (1) KR102552795B1 (pl)
CN (1) CN109715639B (pl)
AU (1) AU2017331930B2 (pl)
CA (1) CA3037794A1 (pl)
CL (1) CL2019000728A1 (pl)
CY (1) CY1125052T1 (pl)
DK (1) DK3515924T3 (pl)
EA (1) EA201990723A1 (pl)
ES (1) ES2908572T3 (pl)
HR (1) HRP20220234T1 (pl)
HU (1) HUE057772T2 (pl)
IL (1) IL265445B2 (pl)
LT (1) LT3515924T (pl)
MA (1) MA46266B1 (pl)
MX (1) MX381590B (pl)
MY (1) MY193080A (pl)
PH (1) PH12019500567B1 (pl)
PL (1) PL3515924T3 (pl)
PT (1) PT3515924T (pl)
RS (1) RS62946B1 (pl)
SI (1) SI3515924T1 (pl)
TW (1) TWI752086B (pl)
UA (1) UA124073C2 (pl)
WO (1) WO2018055016A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3515924T (pt) 2016-09-22 2022-03-11 Idorsia Pharmaceuticals Ltd Formas cristalinas
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
EP4181872B1 (en) 2020-07-15 2025-11-26 Viatris Asia Pacific Pte. Ltd. Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist
MX2024000653A (es) 2021-07-13 2024-01-31 Idorsia Pharmaceuticals Ltd Un proceso para la sintesis de ester de butilo de acido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidin-1-il)-2-fenil-pirimidin-4-c arbonil]-amino}-3-fosfono-propionil)-piperazin-1-carboxilico.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
DE60022508T2 (de) 1999-06-14 2006-06-08 Eli Lilly And Co., Indianapolis Inhibitoren von serin proteasen
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
ES2348942T3 (es) 2002-12-11 2010-12-17 Bayer Schering Pharma Aktiengesellschaft Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor plaquetario de adenosin difosfato.
CA2521313A1 (en) 2003-04-09 2004-10-28 Wyeth Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.o)non-1(7)-3n-2-yl)-al kyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
WO2007046075A1 (en) 2005-10-21 2007-04-26 Actelion Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
MX2009011089A (es) 2007-04-23 2009-10-30 Sanofi Aventis Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12.
CN101868469B (zh) 2007-11-29 2014-04-02 埃科特莱茵药品有限公司 膦酸衍生物及其作为p2y12受体拮抗剂
WO2009080227A2 (en) 2007-12-26 2009-07-02 Sanofi-Aventis Pyrazole-carboxamide derivatives as p2y12 antagonists
WO2009080226A2 (en) 2007-12-26 2009-07-02 Sanofis-Aventis Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
MA33260B1 (fr) 2009-04-08 2012-05-02 Actelion Pharmaceuticals Ltd 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
SG175297A1 (en) 2009-04-22 2011-12-29 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
PT3515924T (pt) 2016-09-22 2022-03-11 Idorsia Pharmaceuticals Ltd Formas cristalinas
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
EP4181872B1 (en) 2020-07-15 2025-11-26 Viatris Asia Pacific Pte. Ltd. Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist

Also Published As

Publication number Publication date
WO2018055016A1 (en) 2018-03-29
DK3515924T3 (da) 2022-03-21
US11365209B2 (en) 2022-06-21
MA46266B1 (fr) 2022-02-28
JP2019529553A (ja) 2019-10-17
RS62946B1 (sr) 2022-03-31
TW201813965A (zh) 2018-04-16
HRP20220234T1 (hr) 2022-05-13
KR102552795B1 (ko) 2023-07-06
IL265445A (en) 2019-05-30
PH12019500567B1 (en) 2024-01-31
MY193080A (en) 2022-09-26
EP3515924A1 (en) 2019-07-31
US20220275011A1 (en) 2022-09-01
EP3515924B1 (en) 2021-12-15
BR112019004845A2 (pt) 2019-06-04
MX381590B (es) 2025-03-12
AU2017331930B2 (en) 2021-07-15
CA3037794A1 (en) 2018-03-29
TWI752086B (zh) 2022-01-11
CY1125052T1 (el) 2024-02-16
US12227532B2 (en) 2025-02-18
PT3515924T (pt) 2022-03-11
MX2019003093A (es) 2019-07-18
AU2017331930A1 (en) 2019-03-07
HUE057772T2 (hu) 2022-06-28
CL2019000728A1 (es) 2019-07-05
SI3515924T1 (sl) 2022-04-29
EP3981774A1 (en) 2022-04-13
US20250163086A1 (en) 2025-05-22
UA124073C2 (uk) 2021-07-14
US10730896B2 (en) 2020-08-04
NZ750772A (en) 2023-10-27
MA46266A (fr) 2019-07-31
US20210009614A1 (en) 2021-01-14
US20200017534A1 (en) 2020-01-16
IL265445B2 (en) 2024-05-01
LT3515924T (lt) 2022-03-10
JP7097369B2 (ja) 2022-07-07
IL265445B1 (en) 2024-01-01
CN109715639A (zh) 2019-05-03
KR20190052704A (ko) 2019-05-16
EA201990723A1 (ru) 2019-10-31
ES2908572T3 (es) 2022-05-03
CN109715639B (zh) 2022-04-19
PH12019500567A1 (en) 2019-11-18

Similar Documents

Publication Publication Date Title
IL273730A (en) crystalline forms
DK3270751T3 (en) Foodprocessor
AU201710580S (en) Bookrack
SI3380554T1 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
SG10201911417PA (en) Crystalline compounds
IL262674A (en) crystals
GB201614939D0 (en) Crystalline hydrate
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
GB201419174D0 (en) Crystalline forms
HUE066360T2 (hu) Eravaciklin kristályformái
IL265445A (en) crystalline forms
IL253479A0 (en) Crystalline forms of efinconazole
LT3390358T (lt) Kristalinis eravaciklino bis-hidrochloridas
PL3350179T3 (pl) Krystaliczne postacie
DK3430092T3 (en) Coatingsystem
AU201713059S (en) SUNSHADE - square
ZA201902553B (en) Crystalline forms
IL261795A (en) Crystalline form
GB201715010D0 (en) Crystalline forms
GB201708856D0 (en) Seletalisib crystalline forms
HK40009744A (en) Crystalline forms
GB201604759D0 (en) Crystalline compounds
GB201704789D0 (en) Crystalline compounds
AU5499P (en) T15-1218 Bituminaria bituminosa
AU201713060S (en) SUNSHADE - triangle